MA-HOLOGIC
30.9.2021 14:02:04 CEST | Business Wire | Press release
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has launched its expanded Omni® suite, a comprehensive gynecological surgical offering designed to optimize diagnostic and operative hysteroscopy, in Europe, Africa and the Middle East (EMEA). The offering now includes a versatile Omni 30° hysteroscope, the Omni Lok cervical seal and the Omni 5 French seal, which complement the company’s existing portfolio of GYN surgical solutions and extend physicians’ choices.
The Omni hysteroscope portfolio offers improved diagnostic and operative versatility through three interchangeable sheaths ranging from 3.7 to 6 millimeters with 0°, or the new 30°, field of view options. The long 200 millimeter working length further supports adapting the procedure to the patient’s anatomy. This system of interchangeable sheaths enables “see and treat” applications by quickly switching from diagnostic to operative hysteroscopy, even in an outpatient environment, with less need for sterilization. The Omni hysteroscope with its premium HD rod lens is therefore designed to enable an optimal hysteroscopic experience.
The addition of the Omni™ Lok cervical seal and the Omni 5 French seal cap to Hologic’s portfolio supports procedural efficiency. The Omni Lok seal is a first-in-its-class product designed to help maintain uterine distention and improve procedural efficiency in the operating room (OR) by minimizing fluid leakage during hysteroscopic procedures by an average of 94%.1,2 It is compatible with MyoSure® and Omni hysteroscopes. The Omni 5 French Seal Cap also can reduce leakage and backsplash by over 75% when using 5 French tools.3
“The option to ‘see and treat’ is becoming more common across Europe. There is an increasing awareness of the benefits of moving these types of procedures to the out-patient environment and this has been further highlighted by the pandemic. Gynecologists need to have access to a wider range of products that enable them to adapt quickly to the requirements of each patient,” said Tanja Brycker, VP Strategic Development BSH & Surgical - International. “Hologic has consulted extensively with our customers, and the latest additions to the Omni suite of hysteroscopic products were developed based on their feedback. This is especially true for the Omni 30° hysteroscope, which clearly demonstrates our continuing commitment to meeting our customers’ needs. We expect Omni 30° will quickly become a device of choice for use in out-patients by gynecologists across EMEA.”
Managing fluid loss is a critical element of hysteroscopies, as less fluid on floors and the operating table can improve physician estimates of fluid loss, as well as reduce cleanup and OR turnover time. This in turn may help physicians schedule more patients, increasing productivity.1,2
Hologic’s full product suite includes the Omni 30° and 0° hysteroscopes, the Omni Lok cervical seal and the Omni 5 French seal. The Omni Suite is designed to enhance utilization of Hologic’s wider GYN surgical portfolio including the MyoSure® tissue removal system and the Fluent® fluid management system.
For more information on these products and Hologic’s full hysteroscopic procedure portfolio, visit Gynsurgicalsolutions.co.uk .
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com .
Hologic, Fluent, MyoSure, NovaSure, Omni and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Important Safety Information
The Omni® 0° and 30° hysteroscopes are intended to provide viewing of the cervical canal and uterine cavity for the purpose of performing diagnostic and operative procedures. The Omni 0° and 30° hysteroscopes are not appropriate for patients who are exhibiting acute pelvic inflammatory disease or exhibit the following conditions: inability to distend uterus, cervical stenosis, cervical/vaginal infection, uterine bleeding or menses, invasive carcinoma of the cervix, recent uterine perforation, medical contraindications, or intolerance to anesthesia.
The Omni® Lok cervical seal is used during a hysteroscopic procedure to minimize liquid distention media leakage from the cervix. The Omni Lok cervical seal should not be used in a patient with a contraindication to hysteroscopy.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com .
SOURCE: Hologic, Inc.
1
Hologic Data on file. VAR-08420. Physician questionnaire after video introduction to device; N=15
2
Hologic Data on file, VER-09159, bench test utilizing a uterine model; N=22
3
Hologic data on file. VER-10319
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005269/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 16:04:00 CEST | Press release
At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 15:21:00 CEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
